The Change Was Implemented. The Authorization Never Existed.
Investigator reviewed Change Control CC-2023-0156 for Metoprolol Succinate Extended-Release Tablets 50 mg, NDA 021856, including the change control record, supporting risk classification, and regulatory filing determination.
The firm could not produce a risk assessment supporting the Minor classification, a CQA impact analysis, or a regulatory filing impact determination with its documented basis.
21 CFR 211.100(a) requires written procedures for production and process controls. 21 CFR 314.70 governs supplements and changes to approved applications. Absent documentation identifying who authorized the risk classification and filing impact determination, the change control decision cannot be verified during inspection.
A change control authorization documenting the CQA impact analysis, regulatory filing determination with its specific regulatory basis, and named decision owner would have prevented implementation without required prior approval.
The inspector pulled the change control record. The change was approved. Then they asked: "Who authorized this change, and how was the regulatory impact assessed?"
That question ends careers. Not because the change was wrong — but because the authorization logic was never captured as a formal record.
This case file gives you that record.
During inspection of Change Control CC-2023-0156 covering a modification to the granulation endpoint parameter for Metoprolol Succinate Extended-Release Tablets 50 mg, NDA 021856, the investigator noted the change had been classified as Minor, implemented, and product distributed. The investigator requested documentation of the risk assessment supporting the Minor classification, who authorized that determination, the CQA impact analysis for the granulation modification, and the specific regulatory basis for determining no supplemental filing was required prior to implementation. The change control record contained a risk category checkbox marked "Minor" and a QA approval stamp but no authorization record responsive to any of these questions.
"Who authorized the Minor risk classification for this change, what CQA impact analysis was performed prior to that determination, and what specific regulatory basis supports the conclusion that no supplemental filing was required before implementation?"
For NDA-filed products, a change to a manufacturing process parameter requires evaluation against the approved design space and filed parameter ranges before implementation. The filing impact determination — whether the change requires a Prior Approval Supplement, CBE-30, or CBE-0 — must be documented with its specific regulatory basis and authorized before implementation.
| What Existed | What Was Missing |
|---|---|
| ✓ Change control request CC-2023-0156 opened with technical description of parameter modification | → Risk assessment documenting the basis for the Minor classification |
| ✓ Risk category assigned: Minor | → CQA impact analysis — dissolution, content uniformity, hardness evaluated against change |
| ✓ Implementation plan documented and executed — granulation endpoint modified | → Comparison of modified parameter to filed NDA design space and approved ranges |
| ✓ Product manufactured under revised parameter and distributed to market | → Regulatory filing impact determination with specific 21 CFR 314.70 basis |
| ✓ QA approval stamp on change control closure record | → Named individual who authorized the risk classification and filing determination |
The Decision Ownership Assessment identifies your open decision gaps in 8 minutes.
Take the Assessment → No account required · Results delivered immediately